MedTrace Logo

Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

NCT05314933 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-10-12

No results posted yet for this study

Summary

2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV). The safety and pharmacokinetics of 2-DG are assessed after single or multiple intranasal administrations.

Conditions

  • Acute Nasopharyngitis

Interventions

DRUG

2-Deoxyglucose

Intranasal administration

OTHER

Placebo

Intranasal administration

Sponsors & Collaborators

  • G.ST Antivirals GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2023-08-01
Completion
2023-09-27

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05314933 on ClinicalTrials.gov